Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the verifynow® assay? role of haematocrit and haemoglobin levels

Thrombosis and Haemostasis

Volumn 106, Issue 2, 2011, Pages 227-229

  Voisin, Sophie ^a   Bongard, Vanina ^a   Tidjane, Mohammed A ^a   Lhermusier, Thibault ^a   Carrié, Didier ^a   Sié, Pierre ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Assay; Haematocrit; Haemoglobin; P2Y12; Verifynow

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEMOGLOBIN; PURINERGIC P2Y12 RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST;

AGED; ANALYTICAL PARAMETERS; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HIGH PLATELET REACTIVITY; HUMAN; LEUKOCYTE COUNT; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PERCENT INHIBITION INDEX; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTION UNIT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOSIS; VALIDATION PROCESS; BLOOD; BLOOD CLOTTING PARAMETERS; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION; METABOLISM; METHODOLOGY; STATISTICS; THROMBOCYTE; VALIDATION STUDY;

BLOOD PLATELETS; HEMATOCRIT; HEMOGLOBINS; HUMANS; LEUKOCYTE COUNT; PLATELET COUNT; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12;

EID: 79961047447     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-01-0046     Document Type: Article

References (8)

1. Varenhorst C, James S, Erlinge D, et al. Assessment of P2Y12 inhibition with the point of care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009; 157: 562.e1-562.e9.
2. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
3. Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2008; 52: 1128-1133.
4. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-242.
5. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303 (Suppl): 754-762e.
6. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126.
7. Tidjane MA, Voisin S, Lhermusier T, et al. Dual antiplatelet responsiveness in elderly patients receiving percutaneous intervention. J Thromb Haemost. 2010 9: 614-616
8. Elsenberg EH, van Werkum JW, van de Wal RM, et al. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-712.